SEC filing · 8-K

TScan Therapeutics, Inc.: Executive or director change

TScan Therapeutics entered into separation agreements with its departing Chief Financial Officer and Chief Medical Officer following a strategic reorganization.

Filed September 30, 2026

Neutral news

What happened

TScan Therapeutics formalized separation terms with former Chief Financial Officer Jason A. Amello and former Chief Medical Officer Dr. Chrystal Louis.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to TScan Therapeutics, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.